Inclusion Criteria:  Ability to understand and the willingness to sign a written informed consent document； Age ≥18 years old; Histologically or cytologically confirmed prostate adenocarcinoma; Candidate for androgen deprivation therapy (ADT) for the management of hormone-sensitive prostate cancer； Appropriate serum testosterone and serum PSA concentration at screening as specified in the protocol； Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; Adequate organ performance based on laboratory blood tests; Agree to use adequate contraception prior to study entry and for the duration of study participation.  Exclusion Criteria:  Previously received gonadotropin-releasing hormone analogues (GnRH-a) for more than 12 months total duration (if GnRH-a was received for 12 months or less, then that GnRH-a must have been completed washout period prior to the first dose of study drug). Patients who have received chemotherapy for prostate cancer; History of surgical castration; Received Abiraterone acetate with 3 months prior to the first dose of study drug; Receieved molecular target therapy, immunotherapy, androgen receptor blockade, 5-alpha reductase inhibitors, estrogen, and other investigational compound with 4 weeks prior to the first dose of study drug; Patients with known or suspected brain metastasis； Diagnosis or treatment for another systemic malignancy within 5 years before study treatment initiation; Patients with uncontrolled and clinically significant hypertension and diabetes; Known hypersensitivity to SHR7280, SHR7280 excipients,； History of immunodeficiency (including HIV infection) or organ transplantation; Known active hepatitis B or C infection; Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.